Sector News

Sanofi poaches AstraZeneca scientist as new research head

March 29, 2016
Life sciences

French drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.

Sanofi said on Tuesday that Yong-Jun Liu had been appointed as head of research with effect from April 1, reporting to Elias Zerhouni, the group’s president of global research and development.

Liu, a specialist in immunology with more than 250 published articles in leading academic journals, currently heads up research at AstraZeneca’s MedImmune biotechnology division, a position he has held since 2014.

Prior to that he led programmes at Baylor Research Institute and the MD Anderson Cancer Center, where he was founding director of the Cancer Immunology Research Institute.

His decision to leave AstraZeneca follows the exit last June of Briggs Morrison, the company’s former chief medical officer and head of late-stage drug development, and respiratory and inflammatory medicines head James Ward-Lilley.

AstraZeneca is going through a transition as older drugs lose patent protection and it invests heavily in new medicines, especially in the field of cancer immunotherapy.

It has a promising pipeline of experimental drugs but has also suffered some recent setbacks, including last week’s failure of its marketed heart drug Brilinta as a treatment for stroke patients and earlier disappointing results with a drug to treat lung and abdominal cancer mesothelioma.

Sanofi, meanwhile, is seeking to rejuvenate its early-stage pipeline and Zerhouni said Liu’s experience in immunology, oncology and translational medicine would be “vital assets” for this task.

By Ben Hirschler

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.